Definium Therapeutics, Inc.
A clinical-stage biopharmaceutical company in New York City developing psychedelic-based medicines for psychiatric and neurological disorders. Founded in 2019 as MindMed, a startup exploring LSD and other psychedelics as therapies, it rebranded to Definium Therapeutics in 2026. Its lead program, DT120, is an orally disintegrating tablet of lysergide (LSD) designed to dissolve on the tongue.
Granted 1.20M
Granted 3.27M · Bought 1.0K · Sold 438.4K
Granted 365.0K · Sold 46.0K
Granted 1.07M · Sold 118.1K
Granted 537.5K · Sold 91.1K
Granted 50.0K
Granted 1.45M · Sold 43.0K
Granted 212.5K · Sold 3.0K
Granted 700.0K
Granted 177.5K · Sold 2.9K
Granted 64.7K
Granted 528.4K · Sold 7.0K
Granted 107.6K
Granted 107.6K
Granted 61.4K
Granted 18.5K · Bought 6.0K
Granted 39.9K
Granted 3.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Hu Cynthia W.Chief Legal Officer&Secretary · 1 transaction | — | 1.20Mas of Mar 2022 | 1.20M | — | — |
| Barrow RobertChief Executive Officer, Director · 40 transactions | — | 1.10M | 3.27M | 1.0K | 438.4K |
| Karlin DanielChief Medical Officer · 9 transactions | — | 503.3K | 365.0K | — | 46.0K |
| Karlin DanChief Medical Officer · 26 transactions | — | 338.0Kas of Dec 2024 | 1.07M | — | 118.1K |
| Sullivan MarkChief Legal Officer · 13 transactions | — | 320.6K | 537.5K | — | 91.1K |
| Halperin Wernli MiriExecutive President · 2 transactions | — | 235.0Kas of Aug 2024 | 50.0K | — | — |
| Greenway Schond L.Chief Financial Officer · 9 transactions | — | 211.1Kas of Mar 2024 | 1.45M | — | 43.0K |
| Roberts BrandiChief Financial Officer · 3 transactions | — | 209.5K | 212.5K | — | 3.0K |
| Wernli Miri HalperinExecutive President, Director · 2 transactions | — | 185.0Kas of Mar 2023 | 700.0K | — | — |
| Wiley Matthew T.Chief Commercial Officer · 3 transactions | — | 174.6K | 177.5K | — | 2.9K |
| Makes BrigidDirector · 2 transactions | — | 158.7Kas of Jun 2022 | 64.7K | — | — |
| Liao CarrieChief Accounting Officer · 6 transactions | — | 144.9Kas of Mar 2025 | 528.4K | — | 7.0K |
| Bruhn Suzanne LouiseDirector · 3 transactions | — | 24.3K | 107.6K | — | — |
| Crystal RogerDirector · 3 transactions | — | 24.3K | 107.6K | — | — |
| Vallone Carol ADirector · 3 transactions | — | 21.2K | 61.4K | — | — |
| Gryska David WDirector · 4 transactions | — | 19.9K | 18.5K | 6.0K | — |
| Krebs AndreasDirector · 3 transactions | — | 19.8K | 39.9K | — | — |
| Adsett RogerDirector · 1 transaction | — | 3.6K | 3.6K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 5 years: -742.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.